Statera Biopharma, Inc.: 10-Q filed 2019-11-14

Name: Statera Biopharma, Inc.: 10-Q filed 2019-11-14
Creator: Statera Biopharma, Inc.

What Statera Biopharma, Inc. reported in its quarterly report filed 2019-11-14 (fiscal Q3 2019): 30 published measures, 93 facts as tagged in accession 0001437749-19-022938.

This filing

Form: 10-Q (quarterly report)
Filed: 2019-11-14
Fiscal period: fiscal Q3 2019
Accession: 0001437749-19-022938 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Statera Biopharma, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2019-09-30	2,228,772	USD
At 2018-12-31	4,534,407	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2019-09-30	565,682	USD
At 2018-12-31	920,380	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2019-09-30	-3,363,169	USD
At 2018-12-31	-1,451,945	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2019-09-30	1,487,388	USD
At 2018-12-31	3,617,234	USD
At 2018-09-30	4,378,739	USD
At 2017-12-31	4,230,548	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	-449,919	USD	92
2019-01-01 to 2019-09-30	-1,939,690	USD	273
2018-07-01 to 2018-09-30	-1,104,444	USD	92
2018-01-01 to 2018-09-30	-3,180,091	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2019-01-01 to 2019-09-30	-2,298,935	USD	273
2018-01-01 to 2018-09-30	-3,441,076	USD	273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	269,635	USD	92
2019-01-01 to 2019-09-30	744,521	USD	273
2018-07-01 to 2018-09-30	283,307	USD	92
2018-01-01 to 2018-09-30	902,474	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2018-01-01 to 2018-09-30	55,215	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2019-01-01 to 2019-09-30	158,544	USD	273
2018-01-01 to 2018-09-30	3,560,750	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2019-09-30	-165,998,275	USD
At 2018-12-31	-164,058,585	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2019-07-01 to 2019-09-30	USD	92
2019-01-01 to 2019-09-30	USD	273
2018-07-01 to 2018-09-30	USD	92
2018-01-01 to 2018-09-30	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2019-09-30	17,445	USD
At 2018-12-31	27,747	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	-518,396	USD	92
2019-01-01 to 2019-09-30	-2,080,169	USD	273
2018-07-01 to 2018-09-30	-1,267,766	USD	92
2018-01-01 to 2018-09-30	-4,171,912	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2019-09-30	2,192,660	USD
At 2018-12-31	4,476,287	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2019-09-30	565,682	USD
At 2018-12-31	911,921	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2019-09-30	99,529	USD
At 2018-12-31	139,120	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2019-09-30	210,805	USD
At 2018-12-31	251,846	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	788,031	USD	92
2019-01-01 to 2019-09-30	2,824,690	USD	273
2018-07-01 to 2018-09-30	1,551,073	USD	92
2018-01-01 to 2018-09-30	5,074,386	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	262,410	USD	92
2019-01-01 to 2019-09-30	1,375,409	USD	273
2018-07-01 to 2018-09-30	839,413	USD	92
2018-01-01 to 2018-09-30	3,084,790	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2019-09-30	11,298,239	shares
At 2018-12-31	11,298,239	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2019-09-30	-582,904	USD
At 2018-12-31	-611,370	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit
At 2019-09-30	1,663,090	USD
At 2019-06-30	2,142,451	USD
At 2019-03-31	2,761,465	USD
At 2018-12-31	3,614,027	USD
At 2018-09-30	4,096,388	USD
At 2018-06-30	5,259,674	USD
At 2018-03-31	6,213,483	USD
At 2017-12-31	7,408,370	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2019-09-30	18,667	USD
At 2018-12-31	30,373	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2019-09-30	441,692	USD
At 2018-12-31	694,164	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	-467,367	USD	92
2019-01-01 to 2019-09-30	-1,994,273	USD	273
2019-04-01 to 2019-06-30	-633,594	USD	91
2019-01-01 to 2019-03-31	-893,312	USD	90
2018-07-01 to 2018-09-30	-1,128,361	USD	92
2018-01-01 to 2018-09-30	-3,259,398	USD	273
2018-04-01 to 2018-06-30	-872,585	USD	91
2018-01-01 to 2018-03-31	-1,258,452	USD	90

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	-458,080	USD	92
2019-01-01 to 2019-09-30	-1,911,224	USD	273
2018-07-01 to 2018-09-30	-1,128,247	USD	92
2018-01-01 to 2018-09-30	-3,252,533	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	525,621	USD	92
2019-01-01 to 2019-09-30	1,449,281	USD	273
2018-07-01 to 2018-09-30	711,660	USD	92
2018-01-01 to 2018-09-30	1,989,596	USD	273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2019-01-01 to 2019-09-30	10,303	USD	273
2018-01-01 to 2018-09-30	14,084	USD	273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	14,246	USD	92
2019-01-01 to 2019-09-30	32,528	USD	273
2018-07-01 to 2018-09-30	16,191	USD	92
2018-01-01 to 2018-09-30	109,591	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	51,029	USD	92
2019-01-01 to 2019-09-30	85,896	USD	273
2018-07-01 to 2018-09-30	139,405	USD	92
2018-01-01 to 2018-09-30	912,514	USD	273

Inspect the source

Entity: Statera Biopharma, Inc. / CIK 0001318641
Captured: 2026-09-22 19:44 UTC
SEC response SHA-256: 9e499247f86d1cf9ca87ba87bfcdf37d42baa7907f4baa6e983f1992a49045f7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001318641.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))